» Articles » PMID: 34520320

A Bivalent Live-attenuated Vaccine Candidate Elicits Protective Immunity Against Human Adenovirus Types 4 and 7

Overview
Date 2021 Sep 14
PMID 34520320
Authors
Affiliations
Soon will be listed here.
Abstract

Human adenovirus types 4 (HAdV4) and 7 (HAdV7) often lead to severe respiratory diseases and occur epidemically in children, adults, immune deficiency patients, and other groups, leading to mild or severe symptoms and even death. However, no licensed adenovirus vaccine has been approved in the market for general use. E3 genes of adenovirus are generally considered nonessential for virulence and replication; however, a few studies have demonstrated that the products of these genes are also functional. In this study, most of the E3 genes were deleted, and two E3-deleted recombinant adenoviruses (ΔE3-rAdVs) were constructed as components of the vaccine. After E3 deletion, the replication efficiencies and cytopathogenicity of ΔE3-rAdVs were reduced, indicating that ΔE3-rAdVs were attenuated after E3 genes deletion. Furthermore, single immunization with live-attenuated bivalent vaccine candidate protects mice against challenge with wild-type human adenovirus types 4 and 7, respectively. Vaccinated mice demonstrated remarkably decreased viral loads in the lungs and less lung pathology compared to the control animals. Taken together, our study confirms the possibility of the two live-attenuated viruses as a vaccine for clinic use and illustrates a novel strategy for the construction of an adenovirus vaccine.

Citing Articles

Construction of a bivalent vaccine candidate against HAdV4/HAdV7 based on capsid-display strategy via Red-homologous recombination and counter-selection methodology.

Wang P, Shao Y, Yang X, Zhang W, Zhou J, Huang F Biosaf Health. 2025; 6(2):70-79.

PMID: 40078946 PMC: 11895023. DOI: 10.1016/j.bsheal.2024.02.001.

References
1.
Heindl L, Augustin A, Messmer E . ADenoVirus Initiative Study in Epidemiology (ADVISE)-results of a multicenter epidemiology study in Germany. Graefes Arch Clin Exp Ophthalmol. 2018; 257(1):249-251. DOI: 10.1007/s00417-018-4150-2. View

2.
Yeh M, Bujaki E, Dolan P, Smith M, Wahid R, Konz J . Engineering the Live-Attenuated Polio Vaccine to Prevent Reversion to Virulence. Cell Host Microbe. 2020; 27(5):736-751.e8. PMC: 7566161. DOI: 10.1016/j.chom.2020.04.003. View

3.
Liu T, Zhou Z, Tian X, Liu W, Xu D, Fan Y . A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine. 2018; 36(16):2199-2206. DOI: 10.1016/j.vaccine.2018.02.050. View

4.
Cai R, Mao N, Dai J, Xiang X, Xu J, Ma Y . Genetic variability of human adenovirus type 7 circulating in mainland China. PLoS One. 2020; 15(4):e0232092. PMC: 7192419. DOI: 10.1371/journal.pone.0232092. View

5.
Zhang J, Kang J, Dehghan S, Sridhar S, Lau S, Ou J . A Survey of Recent Adenoviral Respiratory Pathogens in Hong Kong Reveals Emergent and Recombinant Human Adenovirus Type 4 (HAdV-E4) Circulating in Civilian Populations. Viruses. 2019; 11(2). PMC: 6410123. DOI: 10.3390/v11020129. View